Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 2/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | PYCR1 | P32322 | 2/20 | 0.38 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.38 |
| ▸ | TGM2 | P21980 | 3/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | F13A1 | P00488 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | TGM1 | P22735 | 1/20 | 0.32 |
| ▸ | TGM3 | Q08188 | 1/20 | 0.32 |
| ▸ | MMP9 | P14780 | 2/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5879213 | 0.87 | HTR2A (0.47) | CYP2C19HTR2APYCR1CYP1A2SMN1; SMN2 | |
| SCHEMBL5879215 | 0.87 | HTR2A (0.47) | CYP2C19HTR2APYCR1CYP1A2SMN1; SMN2 | |
| SCHEMBL6986752 | 0.87 | HTR2A (0.47) | CYP2C19HTR2APYCR1CYP1A2SMN1; SMN2 | |
| SCHEMBL21551717 | 0.79 | GABBR2 (0.39) | CYP2C19SMN1; SMN2 | |
| SCHEMBL2150854 | 0.79 | ESR1 (0.44) | CYP2C19CYP1A2SMN1; SMN2LMNA | |
| SCHEMBL8635387 | 0.79 | TYR (0.41) | CYP2C19SMN1; SMN2ATML3MBTL1 | |
| SCHEMBL9003499 | 0.78 | CYP2C19 (0.55) | CYP2C19HTR2ACYP1A2SMN1; SMN2ATM | |
| SCHEMBL13662800 | 0.77 | HRH3 (0.44) | CYP2C19HTR2APYCR1CYP1A2 | |
| SCHEMBL5153023 | 0.77 | HRH3 (0.44) | CYP2C19HTR2APYCR1CYP1A2 | |
| SCHEMBL15184685 | 0.77 | HRH3 (0.44) | CYP2C19HTR2APYCR1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8283358-B2 | N-sulfonamido polycyclic pyrazolyl compounds | ELAN PHARMACEUTICALS, INC. (US) | 2012-10-09 | — | — | US | disclosed |
| EP-2346863-A2 | N-SULFONAMIDO POLYCYCLIC PYRAZOLYL COMPOUNDS | Elan Pharmaceuticals Inc. (US) | 2011-07-27 | — | — | EP | disclosed |
| US-20100081680-A1 | N-SULFONAMIDO POLYCYCLIC PYRAZOLYL COMPOUNDS | ELAN PHARMACEUTICALS, INC. | 2010-04-01 | — | — | US | disclosed |
| WO-2010028213-A2 | N-SULFONAMIDO POLYCYCLIC PYRAZOLYL COMPOUNDS | ELAN PHARMACEUTICALS, INC. (US) | 2010-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100081680-A1 | N-SULFONAMIDO POLYCYCLIC PYRAZOLYL COMPOUNDS | PSEN1, PSEN2, SULT1E1 | CYP2C19 191/4885HTR2A 840/4885PYCR1 53/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.